Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Poster Session B

Systemic lupus erythematosus (SLE)

Session: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

1485: Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis

Monday, November 13, 2023
9:00 AM – 11:00 AM PT
Location: Poster Hall
On Demand In Person
CLAUDIA MENDOZA PINTO1, Pamela Munguía-Realpozo1, Ivet Etchegaray-Morales2, Mario García-Carrasco2 and Socorro Méndez Martínez1, 1Instituto Mexicano del Seguro Socia, Puebla, Mexico, 2Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that increases the risk of severe clinical outcomes and mortality. However, the association between SLE and the risk of diabetes mellitus (DM) is unclear. Our study aimed to investigate the risk of DM and to evaluate the impact of SLE therapies on the risk of developing DM in patients with SLE.

Methods: Electronic database searches of PubMed, Embase, Cochrane Library, and Web of Science, together with hand search, were performed from inception to February 2023. Studies analyzing the relationships between risk factors for DM in SLE patients in cohort or case-control were included. Data were pooled utilizing fixed- or random-effects metanalysis to estimate pooled relative risk (RR) and 95% confidence intervals (CIs). The study was registered with PROSPERO, CRD42023402774.

Results: A total of 36 studies (23 case-control and 13 cohort studies) involving 265,822 patients with SLE were included. In the pooled analysis from case-control studies, we found a greater risk (OR = 1.05, 95% CI 0.87-1.27; P = 0.63) of diabetes in patients with SLE compared with non-SLE controls. However, the pooled risk estimate of cohort studies did not show a significant risk of DM (RR= 1.32, 95% CI 0.93-1.87; P = 0.12). In a subgroup analysis, reduced risk of diabetes was reported with antimalarials (RR= 0.56, 95% CI 0.42-0.75; P < 0.001), while glucocorticoids use was associated with an increased risk of developing diabetes (RR= 1.45, 95% CI 1.20-1.76; P = 0.0002). Age, sex, hypertension, and immunosuppressants were not associated with DM in SLE patients.

Conclusion: Although there was not an increased risk of DM in overall SLE patients compared to controls, antimalarials users or adherents had a decreased risk, while GCT users had an increased risk.


Forest plot of DM risk in SLE patients treated with glucocorticoids


C. MENDOZA PINTO: None; P. Munguía-Realpozo: None; I. Etchegaray-Morales: None; M. García-Carrasco: None; S. Méndez Martínez: None.